Daehan New Pharm Co. Ltd (054670) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daehan New Pharm Co. Ltd stock KRW 9,109, price KRW 5,010, upside +81.8%, quality 37 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 5,010 KRW – 12,911 KRW · fair‑value band 8,362 KRW – 10,663 KRW · the 5,010 KRW price screens below the 9,109 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Daehan New Pharm Co. in your weekly email
Every Wednesday you see whether Daehan New Pharm Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally.
Show moreShow less
It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products.
The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025.
Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
Daehan New Pharm Co. Ltd (054670) currently trades at 5,010 KRW, while our model-based Fair Value estimate is 9,109 KRW, implying the stock looks roughly 45% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 20,515 KRW per share, and 12 of the 16 models we run sit above the 5,010 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,193 KRW, and 4 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 8,362 KRW (bear) to 10,663 KRW (bull), the price of 5,010 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daehan New Pharm Co. Ltd reported revenue of 202B KRW in FY2025 versus 167B KRW in FY2021, a compound +5.0%/yr. Reported net income was 15.3B KRW in FY2025, compounding −0.7%/yr from FY2021.
Key figures
Market cap 70.3B KRW (≈ $52.0M) Micro · P/E ratio 2.9 · P/S ratio 0.33 · EPS (TTM) 1,705 KRW · Dividend yield 2.0% · Net margin 11.3% · Return on equity 17.4% · Return on assets (EBIT) 12.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 82%, 054670 screens cheaper than that median.
Fair Value models
Bear8,362 KRWFair Value 9,109 KRWBull10,663 KRW
Price 5,010 KRW · Upside +81.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1,377 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.3%
Dividend (yield on the price)2.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 6%
Compare Daehan New Pharm Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside+81.8% · Top 25%
Profitability
Return on equity (12 months)17.4% · Top 25%
Return on assets5.6% · Above median
Net margin (12 months)11.3% · Above median
Operating margin (12 months)3.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)12.2% · Above median
Dividend yield (12 months)2.0% · Above median
Balance sheet
Debt / equity0.39× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daehan New Pharm Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/054670
Frequently asked questions
Is Daehan New Pharm Co. Ltd (054670) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 9,109 KRW versus a price of 5,010 KRW, about +82% upside (undervalued).
What is the fair value of 054670?
Our model-based fair value for Daehan New Pharm Co. Ltd is 9,109 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 5,010 KRW.
What is the quality score of 054670?
Daehan New Pharm Co. Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daehan New Pharm Co. Ltd (054670)?
Our model-based price target is the fair value of 9,109 KRW (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 8,362 KRW, optimistic scenario 10,663 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daehan New Pharm Co. Ltd stock forecast for 2026?
Our models put fair value at 9,109 KRW, about +82% upside versus a price of 5,010 KRW (undervalued). Cautious scenario 8,362 KRW, optimistic scenario 10,663 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daehan New Pharm Co. Ltd (054670)?
Daehan New Pharm Co. Ltd reported trailing-twelve-month revenue of about 211B KRW (latest available figure, as of Nov 9, 2026).
Does Daehan New Pharm Co. Ltd pay a dividend?
Daehan New Pharm Co. Ltd currently shows a dividend yield of 2.00% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Daehan New Pharm Co. Ltd (054670) and when is the ex-dividend date?
Daehan New Pharm Co. Ltd pays a dividend of 100.00 KRW per share a year, a dividend yield of 2.0%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since 2021. The payout ratio is 5.9% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Daehan New Pharm Co. Ltd (054670)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daehan New Pharm Co. Ltd it is 9,109 KRW per share (as of Nov 9, 2026), against a price of 5,010 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daehan New Pharm Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 054670 trades below its calculated fair value: price 5,010 KRW, fair value 9,109 KRW, a gap of about +82% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 054670?
No. The price is what the market pays today (5,010 KRW); the fair value is what the company's own numbers justify (9,109 KRW). For Daehan New Pharm Co. Ltd the two are 4,099 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daehan New Pharm Co. Ltd worth?
The market values Daehan New Pharm Co. Ltd at about 70.3B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 5,010 KRW; our models calculate a fair value of 9,109 KRW per share.
What do the bullish and bearish scenarios say about 054670?
Our models span a range for Daehan New Pharm Co. Ltd: cautious scenario 8,362 KRW, base 9,109 KRW, optimistic 10,663 KRW per share (as of Nov 9, 2026, price 5,010 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 054670?
Daehan New Pharm Co. Ltd trades at a price-to-earnings ratio of 2.9 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9,109 KRW is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2018 to 2025), reported earnings: 9.6. Other multiples: P/B 0.5, P/S 0.3, EV/EBITDA 7.2.
How solid is the balance sheet of Daehan New Pharm Co. Ltd (054670)?
Balance-sheet figures for Daehan New Pharm Co. Ltd (as of Nov 9, 2026): return on equity 17.4%, debt of 0.39 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 054670 from its 52-week high?
Daehan New Pharm Co. Ltd trades at 5,010 KRW, about 33% below its 52-week high of 7,510 KRW and at the low of 5,010 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 9,109 KRW is for.
Which stocks are comparable to Daehan New Pharm Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daehan New Pharm Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 5,010 KRW, calculated fair value 9,109 KRW (+82%), Quality Score 37/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 054670 calculated?
We run Daehan New Pharm Co. Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 9,109 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daehan New Pharm Co. Ltd currently trades 45% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daehan New Pharm Co. Ltd (054670)?
The closing price on Nov 6, 2026 was 5,010 KRW. Our model-based fair value is 9,109 KRW, about +82% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daehan New Pharm Co. Ltd right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (8,362 KRW). The market is more pessimistic than our downside scenario.
Key figures of Daehan New Pharm Co. Ltd
How large is the market capitalisation of Daehan New Pharm Co. Ltd (054670)?
The market capitalisation of Daehan New Pharm Co. Ltd is 70.3B KRW (≈ $52.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daehan New Pharm Co. Ltd (054670)?
The price-to-sales ratio of Daehan New Pharm Co. Ltd is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daehan New Pharm Co. Ltd (054670)?
Earnings per share at Daehan New Pharm Co. Ltd are 1,705 KRW (price ÷ EPS = P/E 2.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daehan New Pharm Co. Ltd (054670)?
The dividend yield of Daehan New Pharm Co. Ltd is 2.0% (payout 5.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daehan New Pharm Co. Ltd (054670)?
The net margin of Daehan New Pharm Co. Ltd is 11.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daehan New Pharm Co. Ltd (054670)?
The return on equity (ROE) of Daehan New Pharm Co. Ltd is 17.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daehan New Pharm Co. Ltd (054670)?
On an EBIT basis the return on assets of Daehan New Pharm Co. Ltd is 12.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daehan New Pharm Co. Ltd (054670)?
The operating margin of Daehan New Pharm Co. Ltd is 3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daehan New Pharm Co. Ltd (054670)?
Revenue at Daehan New Pharm Co. Ltd is growing +12.2% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daehan New Pharm Co. Ltd (054670)?
Earnings per share at Daehan New Pharm Co. Ltd are growing +275% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daehan New Pharm Co. Ltd (054670) generate?
The free cash flow of Daehan New Pharm Co. Ltd is −46.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daehan New Pharm Co. Ltd (054670) carry?
The net debt of Daehan New Pharm Co. Ltd is 78.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daehan New Pharm Co. Ltd in the live analysis
One click puts Daehan New Pharm Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026